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Cellular changes in boric acid-treated DU-145 prostate cancer
cells
WT Barranco1 and CD Eckhert*,1
1Department of Environmental Health Sciences, University of California, Los Angeles, Box 951770, CA 90095-1772, USA
Epidemiological, animal, and cell culture studies have identified boron as a chemopreventative agent in prostate cancer. The present
objective was to identify boron-induced changes in the DU-145 human prostate cancer cell line. We show that prolonged exposure
to pharmacologically-relevant levels of boric acid, the naturally occurring form of boron circulating in human plasma, induces the
following morphological changes in cells: increases in granularity and intracellular vesicle content, enhanced cell spreading and
decreased cell volume. Documented increases in b-galactosidase activity suggest that boric acid induces conversion to a senescent-
like cellular phenotype. Boric acid also causes a dose-dependent reduction in cyclins A–E, as well as MAPK proteins, suggesting their
contribution to proliferative inhibition. Furthermore, treated cells display reduced adhesion, migration and invasion potential, along
with F-actin changes indicative of reduced metastatic potential. Finally, the observation of media acidosis in treated cells correlated
with an accumulation of lysosome-associated membrane protein type 2 (LAMP-2)-negative acidic compartments. The challenge of
future studies will be to identify the underlying mechanism responsible for the observed cellular responses to this natural blood
constituent.
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The element boron is nearly completely absorbed from drinking
water and plant-derived foods in the gastrointestinal tract, and
circulates in blood as boric acid (BA) (Price et al, 1997). Cells were
once thought incapable of processing the element, yet this has
since been disproved. Boron is utilised by bacteria in the structure
of several antibiotics and autoinducer-2, a signalling molecule
utilised during interspecies quorum sensing (Chen et al, 2002;
Semmelhack et al, 2004). Plants require the element for growth,
flowering and seed formation, and obtain boron from soil pore
water using a borate transporter, BOR1, expressed in root pericycle
cells (Takano et al, 2002). A human homologue, the electrogenic,
voltage-regulated, Naþ -coupled borate transporter NaBC1, was
recently identified in human kidney tubular cells and may function
to maintain plasma BA levels (Park et al, 2004).
There are several reports supporting boron as a chemopreven-
tative agent against prostate cancer. An epidemiological study
using data from the NHANES III database reported that the risk of
prostate cancer in US men is inversely proportional to dietary
intake of boron (Cui et al, 2004). The biological plausibility of this
observation has been supported by cell culture and animal studies.
Treatment of nude mice, injected with androgen-sensitive LNCaP
prostate cancer cells, with BA caused a reduction in tumour growth
of 25– 38%, along with a reduction in plasma PSA levels of 88%
(Gallardo-Williams et al, 2004). BA inhibits the activity of serine
proteases, including prostate-specific antigen (PSA), presumably
by binding to its active site (Bone et al, 1987; Gallardo-Williams
et al, 2003). In culture, BA has been shown to inhibit the
proliferation of LNCaP and the androgen-independent prostate
cancer cell lines DU-145 and PC-3, in a dose-dependent manner
(Barranco and Eckhert, 2004). Since DU-145 cells do not synthesise
PSA, BA’s mode of inhibiting proliferation is likely not to occur by
inhibiting the conversion of IGFBP-3 to IGF-1, as proposed in
LNCaP tumours (Gallardo-Williams et al, 2004; Sobel and Sadar,
2005). The present investigation was initiated to define morpho-
logical and molecular responses of DU-145 prostate cancer cells to
BA, which might lead to an explanation of its antiproliferative
properties.
In the current report, we examined the effects of pharmacolo-
gical concentrations of BA on cell morphology and molecular
markers of proliferation, senescence, metastasis and motility.
We show that prolonged exposure to BA causes DU-145 cells to
develop a flattened, angular phenotype with numerous vesicles
appearing in the cytoplasm. These changes occur coincident with a
decrease in the expression of cyclin proteins, p21 and P-MEK1/2,
as well as a reduction in cell motility and invasion capacity. Finally,
increased b-galactosidase activity reflects a conversion of DU-145s
to a senescence-like cell.
MATERIALS AND METHODS
Experimental culture
DU-145, LNCaP, and PC-3 PCa cells, donated by Dr Allan Pantuck,
were cultured in RPMI 1640 media (Invitrogen, USA) supple-
mented with 10% FBS, penicillin/streptomysin (100 U ml1;
100mg ml1), and L-glutamine (200 mM) (Gemini Bioproducts,
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USA). Experimental media was prepared as previously published
in Barranco and Eckhert (2004). Cells were plated directly onto
culture plates or glass coverslips and allowed to settle overnight in
nontreated media. After 24 h, media was aspirated and replaced
daily, for 7–8 days, with BA-supplemented media (0– 1000mM).
Cell counts were performed using a hemacytometer and Trypan
Blue (Invitrogen) for identifying nonviable cells.
Flow cytometry
Following 8 days in culture with BA (0, 250, and 1000 mM), DU-145
cells were trypsinised, resuspended as 1 ml aliquots (106 cells ml1)
in loading buffer (RPMI 1640 w/o phenol red), and incubated in
12 75 mm polystyrene test tubes for 30 min, at 371C, 5% CO2.
Following incubation, forward light scatter and side light scatter
analysis (serving as measures of cell size and granularity,
respectively) were determined using a Becton Dickinson BD-LSR
analytic flow cytometer on samples of 10 000 cells. Data analysis
was performed with FLOWJO. Loading buffer was supplemented
with Indo-1 AM (1 mM) (Sigma, USA), a cell-permeable Ca2þ
fluorescent probe, for concordant measurements of intracellular
calcium.
b-galactosidase assay
Detection of b-galactosidase activity was determined using a
previously published procedure (Dimri et al, 1995). DU-145 cells
(8-day exposed), cultured on glass coverslips, were washed in PBS
and fixed in 3% formaldehyde for 5 min. Fixed cells were washed
with PBS and incubated overnight at 371C (low CO2) with fresh
b-Gal stain solution (1 mg ml1 5-bromo-4-chloro-3-indoyl b-D-
galactopyranoside (X-Gal), 40 mM citric acid/40 mM sodium
phosphate (pH 4.0 & 6.0), 5 mM potassium ferrocyanide, 5 mM
potassium ferricyanide, 150 mM NaCl, 2 mM MgCl2). The percen-
tage of cells testing positive for b-galactosidase activity (appearing
blue) in four randomly selected optical fields were determined
under light microscopy.
Western blot
DU-145 cells were cultured for 1, 2, and 7 days in the presence of
BA (0–1000 mM), on 100 20 mm tissue culture plates, with daily
media replacement. Following treatment, monolayers were washed
with PBS, removed with a rubber policeman, and centrifuged at
1200 rpm for 5 min. For protein extraction, pellets were submerged
in lysis buffer (250 mM NaCl, 0.1% NP40, 50 mM HEPES (pH 7.0),
5 mM EDTA, 1 mM DTT, 10% protease inhibitor mixture (Sigma)),
sonicated, and incubated for 40 min at 41C. Wells of 10% stacking,
12% separating (SDS –PAGE) gels were loaded with 30 mg of
protein per sample and separated for 30 min at 100 V, followed by
1 h at 200 V. Separated proteins were transferred to nitrocellulose
membranes for 4 h at 40 V, 41C. Membranes were blocked
overnight (Nonfat dry milk 4 g, 38 mM Tris base, 125 mM NaCl
2.5, 100ml Tween 20, ddH2O 100 ml). The 2-h primary antibody
exposure (1/200 –1/800 dilution) was followed by a 10 min wash in
PBS/Tween 20 (0.1%) and 1-h secondary antibody exposure (1/
1000 dilution) was followed by 3 10 min washes in PBS/Tween 20
(0.1%). Probed membranes were submerged in ECL detection
reagent, (Amersham, USA), wrapped in cellophane, and exposed to
X-ray film (Fuji). All primary and secondary antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Fluorescent probe detection of actin and acidic
compartments
For actin probing (F-actin, fluorescein phalloidin; G-actin,
fluorescent deoxyribonuclease I conjugate) (Molecular Probes,
USA), 8-day BA-treated DU-145 cells were washed 2 with PBS
and fixed in PBS containing 3.7% formaldehyde, for 10 min at
room temperature. Fixed cells were washed 2 with PBS before
being extracted with acetone (201C) for 5 min. 2 wash with
PBS followed before cells were loaded with phalloidin (0.16 mM in
1% BSA/PBS) or deoxyribonuclease I (0.3 mM in glycerol/PBS) for
20 min, at 371C. Loaded cells were washed 2 with PBS, mounted
on slides, and viewed under confocal microscopy (Fluorescein: ex
496, em 516).
For intracellular acidic compartment labelling, 8-day BA-
exposed DU-145 cells were loaded with a nonspecific lysosome
marker (LysoTracker Green) (Molecular Probes). Cells were
submerged in prewarmed media containing LysoTracker (1 mM)
for 1 h, at 371C. Following incubation, loading medium was
aspirated, replaced with PBS, and cells were viewed under confocal
microscopy (ex 504, em 511). All fluorescent images, along with
light images, were recorded using an Axioskop 2 FS confocal
microscope and brightened using Photoshop 6.0.
Cell attachment, migration, and invasion assays
For cell attachment efficiency calculations, DU-145 cells were
cultured in the presence of BA (0, 250, and 1000mM) for 8 days on
100 20 mm tissue culture plates, trypsinised and replated onto six-
well polystyrene culture plates (Fisher, USA) at 2.5 105 cells well1.
Following a 24-h incubation, nonadherent cells and media were
aspirated, while attached cells were trypsinised and counted.
The migration analysis protocol was identical to the attachment
assay’s, except that 2.5 105 cells were loaded in the upper
migration chamber of a Corning transwell permeable support (24-
well transwell, 8-mM polycarbonate membrane) in 0.1 ml of serum-
free RPMI-1640 media. RPMI-1640 (0.6 ml) supplemented with
10% FBS, serving as a chemo-attractant, was deposited in the lower
chamber. Plates were covered and incubated for 24 h at 371C, 5%
CO2. Following incubation, cells remaining on the upper filter were
removed with a cotton swab, while the migrated population on the
filter underside was washed with PBS, fixed in methanol, stained
with Giemsa stain, rinsed with PBS, and deionised water, and
allowed to air-dry. Cells in four random optical fields were counted
to determine the number of migratory cells.
The invasion assay procedure was identical to that used in the
migration analysis, except that each filter, prior to loading, was
coated with 20 mg of growth factor reduced-matrigel (BD
biosciences) in 100 ml of cold, serum-free RPMI-1640 media, and
subsequently allowed to air-dry overnight in a sterile culture hood.
Since plating efficiency varied among BA-treated cells on
matrigel-treated and untreated polycarbonate membranes, test
cells were cultured alongside experimental cells and after
incubation were trypsinised from filters, counted on a haema-
cytometer and used to determine the motility fraction.
Media pH measurements
Following 8-day BA (250 and 1000 mM) exposures to DU-145 cells,
with daily media refreshment, media used for the 24 h period
between day 7 and 8 was removed and the pH was measured using
a Pinnacle 530 pH meter (Corning). Cell counts were performed
on the adherent cells from corresponding plates and utilised for
calculating the pH shift per cell:
Acidic pH shift per cell ¼ 7:4  observed pH
Cells per plateð106Þ :
Statistics
SigmaStat 3.1 statistical software (Systat Software, Point Rich-
mond, CA, USA) was utilised for paired t-test. All experiments
were performed in triplicate.
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RESULTS
BA alters cell morphology, while inducing cellular
senescence
Flow cytometry and light microscopy were used to assess
morphological alterations resulting from BA exposure. Following
an 8-day exposure to BA (0, 250, and 1000mM), flow cytometry
analysis showed a dose-dependent increase in cellular granularity
(side light scatter) and a decrease in cell size (forward light scatter)
(Figure 1A). No differences in cell morphology were apparent
between confocal images of treated and untreated cells during the
first 2 days. By day 8, treated DU-145 cells became flattened and
contained numerous vesicles (Figure 1B).
BA’s ability to inhibit cell proliferation without cell-death
inspired our investigation to determine its effects on markers of
senescence. The activity of b-galactosidase at pH 4.0, a marker of
senescence, increased with BA exposure in a dose-dependent
manner (Figure 1C). Enzyme activity was not detected at pH 6.0
(data not shown).
BA alters proliferation-relevant protein expression
DU-145 cells were exposed to BA (0– 1000mM) for 1, 2, or 7 days.
No changes were apparent at 1 or 2 days, but at 7 days, the protein
expression of cyclins A, B1, C, D1, E, and the phosphorylated
form of MAPK signaler MEK (P-MEK1/2) decreased at 500
and 1000mM concentrations (Figure 2A–F). Phosphorylated ERK
(P-ERK1/2) increased at intermediate exposures (100 and 250 mM),
relative to control, but was reduced by higher concentrations
of BA (Figure 2B). The tumour suppressor gene p53 expression
remained stable, but p21 decreased following 7-day exposures
(Figure 2H).
BA induces cytoskeletal alterations, while inhibiting cell
attachment, migration, and invasion
Measurements were taken to assess cell attachment, migration,
invasion, and intracellular cytoskeletal actin distribution to
determine if BA (250 and 1000 mM) exposure for 8 days had an
effect on metastasis-related aspects of cancer cells. Staining for
filamentous (F)-actin, a marker for intercellular connections and
extensions such as filopodia, was decreased in cells exposed to
high levels of BA. A total of 1000 mM-treated cells had smooth-
edges and were angular in appearance (Figure 3A). Intracellular
globular (G)-actin expression was unaltered by BA exposure.
BA-treated cells show a reduction in attachment efficiency to
polystyrene culture dishes, with a drop in plating efficiency of
34% at 1000mM (Figure 3B). With 10% FBS serving as a chemo-
attractant, the capacity of DU-145 cells to migrate across an 8 mm
polycarbonate permeable membrane was reduced by 28 and 89%,
by 250 and 1000 mM BA, respectively (Figure 3C). The same trend
was observed with invasion potential, where 250 and 1000mM
BA pretreatments reduced matrigel invasion by 82 and 97%
(Figure 3C).
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Figure 1 BA-induced morphological and senescent effects, following 8-day exposure, in DU-145 cells. (A) Dose-dependent increase in granularity, by
way of forward light scatter (FSC-H), and decrease in cell size, by way of side light scatter (SSC-H), from BA (0–1000mM) exposure, as presented on density
plot; mean7s.e.m., n¼ 3. (B) Confocal images (63 ) showing dose-dependent intracellular vesicle accumulation, as indicated by arrows, and flattened
appearance at 8 days of exposure; whereas at 1 and 2 days cells remain unaltered. (C) Dose-dependent b-galactosidase activity (pH 4.0) increase in DU-145
cells; mean7s.e.m., n¼ 4. * Statistically significant from control exposures (P-value o0.001).
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BA induces media acidosis and accumulation of acidic
vesicles
Acidic yellowing of phenol red in culture media was more
pronounced in BA treated cells. The pH of media was measured
prior to (pH 7.4) and following exposure to DU-145 cells for 24 h,
between the 7th and 8th days of culture. The pH for each
concentration of BA (0, 250, and 1000mM) was then converted into
an acidic shift from pH 7.4 per cell value. Chronically BA-exposed
DU-145 cells acidified the surrounding culture media in a dose-
dependent manner (Figure 4A). The number of acidic vesicles
(measured using Lysotracker fluorescent probe) also increased in a
dose-dependent manner, but both the lysosome-specific LAMP-2
protein and early endosome marker EEA1 decreased (Figure 4B
and C). The concentrations of BA used in culture media displays
no significant effect on media pH (data not shown). To exclude the
possibility that BA might alter the buffering capacity of densely
populated culture plates, cells were cultured to near-confluence in
control media before exposure to BA-supplemented media (250
and 1000mM) for 24 h. The pH remained unchanged at all BA
concentrations, showing acidity was not associated with the media,
but instead with cell changes that occurred during the 7 day
exposure (data not shown).
DISCUSSION
Boron has a high affinity for oxygen and is present in aqueous
solution, depending on pH, as either BA (B(OH)3) or borate
(B(OH)4)
. Since the pKa of the equilibrium between B(OH)3 and
borate (B(OH)4)
 is 9.2, at intracellular pH (7.4) free boron exists
as the weak Lewis acid, BA. BA, a small molecule with a mass of
61.83, is rapidly absorbed from the human intestine and excreted
via urine with a half-life of 21 h (Jansen et al, 1984, Schou et al,
1984). There is no evidence supporting metabolism of BA in any
animal species (EPA, 1991). BA does bind to molecules with cis-
hydroxyl groups, as established through mass spectrometry and
NMR analysis identifying a high affinity for the ribose moieties of
NADþ , and a somewhat lower affinity for mononucleotides (Kim
et al, 2003). Nucleotide phosphorylation and loss of charge greatly
reduces substrate affinity for BA (Kim et al, 2004).
Morphology
Flow cytometry analysis showed that BA caused a reduction in cell
volume, yet under light microcopic investigation cells appeared
to have a larger diameter. We believe the DU-145 cell line is
responding to higher concentrations of BA by rearranging its cell
shape into a flattened, low-volume state (Figure 3A). These
structural alterations in shape and size are likely contributing to
the inability of the cells to proliferate, since increased cell volume
and a rounding up from the attached substrate are both critical
events during mitotic division (Lang et al, 2000; Fujibuchi et al,
2005). The observation that morphological alterations did not
appear following 1 and 2 day BA exposures, but did at 8 days,
argues the changes reflect secondary response of long-term
treatment with BA.
The relative intensity of fluorescent staining for G- and F-actin
was found to be unchanged, regardless of BA concentration,
indicating a steady-state actin pool ratio. Although actin
concentrations in general appear unaltered, F-actin-stained
filopodia extending about the periphery of the cells was reduced
by 1000mM BA. With actin serving an important cytoskeletal factor
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Figure 2 BA-induced alterations in proliferation-relevant protein expression, following 1, 2, and 7-day exposure, in DU-145 cells. (A–E) Western blots
show dose-dependent BA-induced (0–1000mM) expression changes of cyclin proteins, (F, G) P-MEK1/2 and P-ERK1/2, and (H) p53 and p21.
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in cell migration and invasion (Lambrechts et al, 2004), the
observed F-actin retraction in BA-treated cells suggests a reduced
capacity to perform either. This interpretation was reinforced by
the analysis showing a dose-dependent inhibitory effect on
motility and invasion capacity, along with incompetence for
reattachment (Figure 3B and C). Together, these results suggest
that BA reduces the metastatic potential of the DU-145 cell.
In BA-treated cells, granularity increased in proportion to
exposure concentration, possibly due to the formation of
intracellular vesicles (Figure 1A and B). The origin and content
of these vesicles is unknown, since fluorescent probes for acidic
compartments, tubulin, and intracellular calcium all failed to
colocalise (data not shown).
Proliferation
The mechanism underlying the antiproliferative activity of BA has
not been elucidated. One of the intriguing properties of BA is its
ability to inhibit proliferation without causing a shift in cell cycle
stage distribution or cell death (Barranco and Eckhert, 2004). In
the current study, BA decreased the expression of five major cyclin
proteins, all presumably playing significant roles in cell cycle
progression (Figure 2A). Furthermore, the ability of antiprolifera-
tive agents to inhibit the expression of these proteins is important,
since cyclins A, B1, E, and D1 have been correlated with prostate
cancer aggressiveness (Mukhopadhyay et al, 2002; Maddison et al,
2004; Tsao et al, 2004).
The DU-145 cell line has a mutant p53 protein incapable of
signalling through p21, so it was nonetheless surprising to see p21
expression reduced by BA exposure (Figure 2B) (Lecane et al,
2003). The downregulation of p21 helps to explain why BA does
not shift DU-145 cell populations into a G1 arrest (Barranco and
Eckhert, 2004, Shukla and Gupta, 2004).
BA’s effects on growth has been shown to be parabolic in
embryonic trout and zebrafish with poor embryonic growth
occurring at very low and high concentrations (U-shaped curve)
(Rowe et al, 1998). BA’s growth effects are cell-type dependent with
maximum growth occurring in Saccharomyces cerevisiae cells at
o0.8 mM BA, whereas 500 mM of BA maximised proliferation in
HeLa cervical cancer cells (Bennett et al, 1999; Park et al, 2004).
Furthermore, in HeLa cells BA (300 mM) was shown to stimulate the
MAPK pathway in a bell-shaped fashion, with an initial induction
of P-MEK1/2 and P-ERK1/2, followed by a decline in expression of
P-MEK1/2 over time. In the present study, BA reduced P-MEK1/2
expression in a dose-dependent manner, yet increased P-ERK1/2
moderately at 250 mM (Figure 2F and G). By way of Ras/Raf
signalling, the phosphorylated form of MEK phosphoylates
ERK, which then translocates to the nucleus and activates
transcription factors relevant in proliferative induction. Thus,
by upregulation of this pathway’s activity, it appears that DU-145
cells are attempting to counter the BA-induced growth inhibi-
tion (Giehl, 2005). Expression of MEK, ERK, and all cyclins were
not altered following 1 and 2 day treatments suggesting, as
observed with cell morphological changes, these were not the
primary effect of BA.
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Senescence
DU-145 cells were evaluated for b-galactosidase activity, a marker
of senescence or reversible cellular quiescence (Coates, 2002).
When enzymatic activity is measured at pH 4.0, it is thought to
indicate an increase in lysosomal enzyme concentration, whereas
enhanced activity at pH 6.0 reflects an increased lysosomal mass
(Kurz et al, 2000). In our study, BA treatment increased the activity
of b-galactosidase in a dose-dependent manner at pH 4.0, yet no
activity was apparent at pH 6.0. However, the dose-dependent
increase recorded at pH 4.0 suggests the BA induces some
‘senescent-like’ characteristics.
Accumulation of acidic intracellular vesicles
A peculiar manifestation of BA treatment was discovered when the
media of chronically exposed DU-145 cells became increasingly
acidic (Figure 4A). This effect was dose-dependent and not due to
changes in the buffering capacity of the media or BA itself. The
documented accumulation of acidic intracellular compartments
is supportive of an affiliation with the media pH shift, by either
contributing directly to the environmental acidification, or rather
resulting from it, as seen in breast cancer cells (Glunde et al, 2003).
Initially, we believed the upregulation of acidic vesicles reflected an
increase in lysosome organelles, yet the LAMP-2 protein, expressed
on lysosomal membranes in prostate tissue, decreased in expres-
sion (Figure 4C) (Furuta et al, 1999). It was also possible that the
acidic vesicles were early endosomes, yet the protein expression of
early endosome marker EEA-1 was likewise reduced (Eskelinen
et al, 2003). Further studies are needed to determine if this response
is unique to cancer cells or a universal response to BA (Gatenby
and Gillies, 2004). Interestingly, metabolic acidosis has been
reported in a case of fatal BA poisoning (Restuccio et al, 1992).
Conclusion
The rationale for this study was based on the fact that BA is (i) a
natural constitute of human blood, (ii) readily absorbed with
plasma levels determined by dietary intake, and (iii) there is
epidemiological, animal, and cell culture evidence supporting its
antiproliferative capacity in prostate cancer. In this report, we
show that pharmacologically-relevant BA treatment causes DU-145
prostate cancer cells to convert to highly granular, low-volume,
flattened cells that have a marked reduction in their capacity to
migrate, invade matrigel, and attach to synthetic substrates.
Reduction in the expression of proliferation-relevant proteins,
along with the upregulation of b-galactosidase activity, ultimately
leads to a nonproliferating entity reminiscent of a senescent-like
cell. Finally, the resulting cell accumulates intracellular acidic
vesicles, while acidifying its extracellular environment.
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Figure 4 BA-induced media pH shifts and acidic vesicle accumulation,
following 8-day exposure, in DU-145 cells. (A) pH shifts from 7.4 (per 106
cells) recorded in BA-supplemented (0–1000 mM) culture media, following
overnight exposure, subsequent to 8-day treatment; mean7s.e.m., n¼ 3.
*Statistically significant from control exposures (P-value o0.009). (B)
Confocal microscopic images of BA-treated cells with Lysotracker
(fluorescent marker of intracellular acidic compartments). (C) 7-day BA
treatments (0–1000mM) led to downregulation of lysosome (LAMP-2) and
the early endosome (EEA1) markers, as shown in Western blots.
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